- Home
- NCLH vs HALO Comparison
NCLH vs HALO Comparison
Compare NCLH & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCLH
- HALO
- Stock Information
- Founded
- NCLH 1966
- HALO 1998
- Country
- NCLH United States
- HALO United States
- Employees
- NCLH N/A
- HALO N/A
- Industry
- NCLH Marine Transportation
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCLH Consumer Discretionary
- HALO Health Care
- Exchange
- NCLH Nasdaq
- HALO Nasdaq
- Market Cap
- NCLH 7.1B
- HALO 7.4B
- IPO Year
- NCLH 2013
- HALO N/A
- Fundamental
- Price
- NCLH $17.32
- HALO $54.54
- Analyst Decision
- NCLH Buy
- HALO Buy
- Analyst Count
- NCLH 18
- HALO 9
- Target Price
- NCLH $26.18
- HALO $63.56
- AVG Volume (30 Days)
- NCLH 15.6M
- HALO 3.3M
- Earning Date
- NCLH 04-30-2025
- HALO 05-06-2025
- Dividend Yield
- NCLH N/A
- HALO N/A
- EPS Growth
- NCLH 120.77
- HALO 55.40
- EPS
- NCLH 1.77
- HALO 3.76
- Revenue
- NCLH $9,415,989,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- NCLH $8.67
- HALO $25.77
- Revenue Next Year
- NCLH $9.74
- HALO $18.01
- P/E Ratio
- NCLH $9.78
- HALO $14.51
- Revenue Growth
- NCLH 5.57
- HALO 25.64
- 52 Week Low
- NCLH $14.21
- HALO $42.01
- 52 Week High
- NCLH $29.29
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- NCLH 44.30
- HALO 44.48
- Support Level
- NCLH $18.86
- HALO $52.43
- Resistance Level
- NCLH $19.68
- HALO $54.26
- Average True Range (ATR)
- NCLH 0.54
- HALO 3.42
- MACD
- NCLH -0.06
- HALO -0.49
- Stochastic Oscillator
- NCLH 18.77
- HALO 30.60
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.